Bill > H75

This bill requires pharmaceutical manufacturers to provide more detailed information in their prescription drug and biological product advertisements in North Carolina. Specifically, manufacturers must disclose the FDA approval date for the drug, the date the drug first became available for consumer purchase, and comprehensive details about clinical trials related to any listed side effects, including the trial's length, number of participants, and the frequency of side effects. The bill defines key terms such as "biological product" (which includes vaccines, blood components, and other medical products), "clinical trial" (a human subject investigation intended for FDA review), "manufacturer" (including those who repackage drugs), and "regulated advertisement" (commercial messages about prescription drugs across various media). These new disclosure requirements aim to provide consumers with more transparent and comprehensive information about prescription drugs and their potential risks, with the regulations set to take effect for advertisements published in North Carolina on or after October 1, 2025.

Government Affairs

https://www.ncleg.gov/BillLookUp/2025/H75